About Eclipse Bio
Eclipse Bio is a company based in San Diego (United States) founded in 2017 by Eric Van Nostrand, Gene Yeo, Alexander Shishkin, and Peter Chu. Eclipse Bio has raised $18.91 million across 5 funding rounds from investors including ARE, HHS and Phoenix Venture Partners. The company has 14 employees as of December 31, 2020. Eclipse Bio offers products and services including eMERGE, eVERSE, End-Seq, and eRibo Pro. Eclipse Bio operates in a competitive market with competitors including Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Correlia Biosystems, among others.
- Headquarter San Diego, United States
- Employees 14 as on 31 Dec, 2020
- Founders Eric Van Nostrand, Gene Yeo, Alexander Shishkin, Peter Chu
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eclipse Bioinnovations, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$18.91 M (USD)
in 5 rounds
-
Latest Funding Round
$4.91 M (USD), Series A
Nov 05, 2025
-
Investors
ARE
& 3 more
-
Employee Count
14
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eclipse Bio
Eclipse Bio offers a comprehensive portfolio of products and services, including eMERGE, eVERSE, End-Seq, and eRibo Pro.
Platform for mRNA and saRNA development challenges
Provides datasets for AI model training in drug discovery
Assay to map unique regulatory regions of RNA
Measures transcription and translation in RNA biology
People of Eclipse Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Eclipse Bio
Eclipse Bio has successfully raised a total of $18.91M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $4.91 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eclipse Bio
Eclipse Bio has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, HHS and Phoenix Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm funding transformative technologies
|
Locked | Locked | Locked | |
|
Tech and life Science focused early stage VC firm investing in the US
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Eclipse Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eclipse Bio
Investment portfolio details for Eclipse Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eclipse Bio
Detailed financials for Eclipse Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eclipse Bio Comparisons
Peer comparison for Eclipse Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eclipse Bio
Eclipse Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abingdon Health, Spear Bio, Olink, Virtue Diagnostics and Correlia Biosystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of immunoassays for diagnostic purposes
|
|
| Locked | Locked | Locked |
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers
|
|
| Locked | Locked | Locked |
Provider of products and services for human protein biomarker research and development
|
|
| Locked | Locked | Locked |
An in vitro assay platform is provided for diagnostic solutions.
|
|
| Locked | Locked | Locked |
Correlia Biosystems is focused on protein quantification technology.
|
Detailed competitors of Eclipse Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eclipse Bio
Complete news archive for Eclipse Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eclipse Bio
Eclipse Bio was founded in 2017.
Eclipse Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Peter Chu is the current CEO of Eclipse Bio. They have also founded this company.
Eclipse Bio is a funded company, having raised a total of $18.91M across 5 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Eclipse Bio is 14.
Eclipse Bio was founded in 2017 in San Diego, United States, within the biotechnology sector. Operations focus on the eCLIP-seq method, a high-throughput sequencing approach that enhances crosslinking and immunoprecipitation for RNA binding protein target identification. Components utilized include cancer cell lines such as HEK293T and K562, human iPSC stem cells, differentiated cells like neurons and cardiomyocytes, and tissues from brain and heart.
Eclipse Bio's top competitors include Abingdon Health, Spear Bio and Olink.
Eclipse Bio offers eMERGE, eVERSE, End-Seq, and eRibo Pro.
Eclipse Bio has 4 investors. Key investors include ARE, HHS, Phoenix Venture Partners, and IGlobe Partners.